Electronic Resource
Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer
| العنوان: | Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer |
|---|---|
| المؤلفون: | Instituto de Salud Carlos III, European Commission, Carrasco, Raquel [0000-0002-2792-5316], Trullas, Ramón [0000-0001-7951-9881], Mengual, Lourdes [0000-0001-7418-9422], Carrasco, Raquel, Ingelmo-Torres, Mercedes, Trullas, Ramón, Roldán, Fiorella L., Rodríguez-Carunchio, Leonardo, Juez, Lourdes, Sureda, Joan, Alcaraz, Antonio, Mengual, Lourdes, Izquierdo, Laura |
| بيانات النشر: | Multidisciplinary Digital Publishing Institute 2023-12-01 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be a feasible strategy to monitor disease progression and therapeutic response in muscle-invasive bladder cancer (MIBC) patients after radical cystectomy (RC). Forty-two MIBC patients who underwent RC were prospectively included. Blood samples from these patients were collected at different follow-up time points. Two specific mutations (TERT c.1-124C>T and ATM c.1236-2A>T) were analyzed in the patients’ plasma samples by droplet digital PCR to determine their ctDNA status. During a median follow-up of 21 months, 24% of patients progressed in a median of six months. ctDNA status was identified as a prognostic biomarker of tumor progression before RC and 4 and 12 months later (HR 6.774, HR 3.673, and HR 30.865, respectively; p < 0.05). Lastly, dynamic changes in ctDNA status between baseline and four months later were significantly associated with patient outcomes (p = 0.045). In conclusion, longitudinal ctDNA analysis using a tumor-agnostic approach is a potential tool for monitoring MIBC patients after RC. The implementation of this testing in a clinical setting could improve disease management and patients’ outcomes. |
| مصطلحات الفهرس: | Bladder cancer, Circulating tumor DNA, Droplet digital PCR, Prognosis, artículo |
| URL: | Publisher's version The underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.3390/ijms242316578 Sí |
| الاتاحة: | Open access content. Open access content http://creativecommons.org/licenses/by/4.0 openAccess |
| ملاحظة: | English |
| Other Numbers: | CTK oai:digital.csic.es:10261/340188 International Journal of Molecular Sciences 24(23): 16578 (2023) 1661-6596 10.3390/ijms242316578 1422-0067 1416002295 |
| المصدر المساهم: | CSIC From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1416002295 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |